Published by Alexander Bueso on 6th June 2022
(Sharecast News) - Analysts at Berenberg reiterated their 'buy' recommendation with a 120.0p target price for shares of AstraZeneca following the release of the company's clinical trial results for its treatment against metastatic breast cancer.
URL: http://www.digitallook.com/dl/news/story/32728044/...